Hemostasis and global fibrinolytic capacity in chronic liver disease

Blood Coagulation and Fibrinolysis

Volumn 18, Issue 7, 2007, Pages 623-626

  Aytac, Sirin ^a   Turkay, Cansel ^b   Bavbek, Nuket ^b,c   Kosar, Ali ^b  

^a GÜVEN HOSPITAL   (Turkey)

^b FATIH UNIVERSITY MEDICAL SCHOOL   (Turkey)

^c NONE   (Turkey)

Author keywords

Global fibrinolytic capacity; Liver

Indexed keywords

ADULT; ARTICLE; BLEEDING; CASE CONTROL STUDY; CHRONIC HEPATITIS; CHRONIC LIVER DISEASE; CLINICAL ARTICLE; CONTROL GROUP; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FIBRINOLYSIS; HEMOSTASIS; HUMAN; LATEX AGGLUTINATION TEST; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MALE; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; STATISTICAL SIGNIFICANCE; THROMBOCYTE COUNT;

ADULT; AGED; BLOOD COAGULATION; BLOOD COAGULATION TESTS; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; FEMALE; FIBRINOLYSIS; HEMOSTASIS; HEPATITIS, CHRONIC; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PARTIAL THROMBOPLASTIN TIME; PLATELET COUNT; PROTHROMBIN TIME;

EID: 34748864147     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/MBC.0b013e328285d80e     Document Type: Article

References (31)

1. Broohy MT, Fiore L, Deykin D. Hemostasis. In: Zakim D, Boyer TD, editors. Hepatology: a textbook of liver disease, 3rd ed. Philadelphia, PA: Saunders; 1996. pp. 691-719.
2. Goodpasture EW. Fibrinolysis in chronic hepatic insufficiency. Bull Johns Hopkins Hosp 1914; 25:330-336.
3. Francis RB Jr, Feinstein DI. Clinical significance of accelerated fibrinolysis in liver disease. Haemostasis 1984; 14:460-465.
4. Violi F, Ferro D, Basili S, Quintarelli C, Musca A, Cordova C, Balsano F. Hiperfibrinolysis increases the risk of gastrointestinal hemorrhage in patients with advanced cirrhosis. Hepatology 1992; 15:672-676.
5. Violi F, Alessandri C, Ferro D, Saliola M, Cordova C, Musca A, Balsano F. Interrelation between factor VII, prekallikrein, and hyperfibrinolysis in advanced cirrhosis. J Clin Pathol 1989; 42:1246-1249.
6. Heisch SL, Kunelis T, Francis RB Jr. The pathogenesis of accelerated fibrinolysis in liver cirrhosis: a critical role for tissue plasminogen activator inhibitor. Blood 1987; 69:1315-1319.
7. Huber K, Kirchheimer JC, Korninger C, Binder BR. Hepatic synthesis and clearance of components of the fibrinolytic system in healthy volunteers and in patients with different stages of liver cirrhosis. Thromb Res 1991; 62:491-500.
8. Leebek FW, Kluft C, Knot EA, de Maat MP, Wilson JH. A shift in balance between profibrinolytic and antifibrinolytic factors causes enhanced fibrinolysis in cirrhosis. Gastroenterology 1991; 101:1382-1390.
9. Tytgat G, Collen D, De Vreker R, Verstraete M. Investigations on the fibrinolytic system in liver cirrhosis. Acta Haematol 1968; 40:265-274.
10. Tran-Thang C, Fasel-Felley J, Pralong G, Hofstetter JR, Bachmann F, Kruithof EK. Plasminogen activators and plasminogen activator inhibitors in liver defficiencies caused by chronic alcoholism or infectious hepatitis. Thromb Haemost 1989; 62:651-653.
11. Knot EA, Drijfhout HR, ten Cate JW, de Jong E, Iburg AH, Kahle LH, Grijm R. Alpha-2 plasmin inhibitor metabolism in patients with liver cirrhosis. J Lab Clin Med 1985; 105:353-358.
12. Marongiu F, Mamusa AM, Mameli G, Mulas G, Solinas A, Demelia L, Contu L. Alpha-2 antiplasmin and disseminated intravascular coagulation in liver cirrhosis. Thromb Res 1985; 37:287-294.
13. Porte RJ, Bontempo FA, Knot EA, Lewis JH, Kang YG, Starzl TE. Systemic effects of tissue plasminogen activator-associated fibrinolysis and its relation to thrombin generation in orthotopic liver transplantation. Transplantation 1989; 47:978-984.
14. Ho CH, Hou MC, Lin HC, Lee FY, Wu JC, Lee SD. Hemostatic changes in patients with liver cirrhosis. Chin Med J 1999; 62:376-382.
15. Amiral J. The global fibrinolytic capacity [abstract]. Fibrinolysis 1996; 10:95.
16. Scarabin PY, Alhenc-Gelas M, Plu-Bureau G, Taisne P, Agher R, Aiach M. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial. Arterioscler Thromb Vasc Biol 1997; 17:3071-3078.
17. Scarabin PY, Vissac AM, Kirzin JM, Bourgeat P, Amiral J, Agher R, Guize L. Elevated plasma fibrinogen and increased fibrin turnover among healthy women who both smoke and use low-dose oral contraceptives - a preliminary report. Thromb Haemost 1999; 82:1112-1116.
18. Amiral J, Malmejac A, Gin H, Pannel R, Vissac A-M, Seigneur M, et al. Evaluation of the fibrinolytic potential on plasma: physiological and pathological variations, and associations with cardiovascular disease risk factors. Fibrinolysis Proteol 1999; 13:1-10.
19. Yurdakok M, Yigit S, Korkmaz A, Kirazli S, Aygun C. Global fibrinolytic capacity in healthy newborn infants. Turk J Pediatr 2001; 43:177-179.
20. Ozatli D, Sayinalp N, Buyukasik Y, Karakus S, Haznedaroglu IC, Kirazli S, et al. Unchanged global fibrinolytic capacity despite increased factor VIIa activity in Behcet's disease: evidence of a prethrombotic state. Rheumatol Int 2002; 21:137-140.
21. Atalar E, Acil T, Aytemir K, Haznedaroglu IC, Ozer N, Kilic H, et al. Diminished global fibrinolytic capacity in patients with mitral valve prolapse is associated with transient ischemic attacks. Clin Appl Thromb Hemost 2002; 8:41-44.
22. Sherlok S, Dooley J. The haematology of liver disease. In: Diseases of the liver and biliary system, 11th ed. Oxford: Blackwell Publishing; 2002. pp. 47-53.
23. Mamen EF. Coagulation defects in liver disease. Med Clin North Am 1994; 78:545-554.
24. Joist JH. AICF and DIC in liver cirrhosis: expressions of a hypercoagulable state. Am J Gastroenterol 1999; 94:2801-2803.
25. Cordova C, Musca A, Violi F, Alessandri C, Vezza E. Improvement of some blood coagulation factors in cirrhotic patients treated with low dose heparin. Scand J Hematol 1982; 29:235-240.
26. Schipper HG, ten Cate JW. Antithrombin III transfusion in patients with hepatic cirrhosis. Br J Haematol 1982; 52:25-33.
27. Van Thiel DH, George M, Fareed J. Low levels of thrombin activable fibrinolysis inhibitor in patients with chronic liver disease. Thromb Haemost 2001; 85:667-670.
28. Morongiu F, Mameli G, Acca MR, Mulas G, Medda A, Tronci MB, et al. Fibrinopeptide A and B in liver cirrhosis. Haemostasis 1988; 18:126-133.
29. Bakker C, Knot E, Stibbe Y, Wilson JH. Disseminated intravascular coagulation in liver cirrhosis. J Hepatol 1992; 15:330-335.
30. Ben-Ari Z, Osman E, Hutton RA, Burroughs AK. Disseminated intravascular coagulation in liver disease: fact or fiction? Am J Gastroenterol 1999; 94:2977-2982.
31. Pirisi M, Fabris C, Ceriello A, Soardo G, Giacomello R, Toniutto P, et al. Deficient antithrombin III activity and enhanced fibrinolysis in patients with liver disease: evidence against a cause-effect relationship. Acta Gastroenterol Belg 1995; 58:236-237.